Key result
Chronic RAAS inhibition with eplerenone, losartan, or both significantly reduced anisotropic reentrant arrhythmia inducibility from 52% in untreated mice to 22%, 26%, and 16%, respectively.
Why the study?
Does chronic RAAS inhibition with eplerenone and/or losartan reduce arrhythmia vulnerability and cardiac fibrosis in senescent mice?
Does chronic RAAS inhibition with eplerenone and/or losartan reduce arrhythmia vulnerability and cardiac fibrosis in senescent mice?
Chronic RAAS inhibition with eplerenone and/or losartan reduces aging-related interstitial fibrosis and arrhythmia inducibility in a senescent mouse model.
Should not alter RAAS use in elderly patients; hypothesis-generating for arrhythmia prevention in age-related remodeling.
Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart. The renin-angiotensin-aldosterone system (RAAS) governs myocardial collagen synthesis. We hypothesized that reducing cardiac fibrosis by chronic RAAS inhibition would result in reduced arrhythmia vulnerability of the senescent mouse heart. Wild-type mice (52 wk old) were treated for 36 wk: 1) untreated control (C); 2) eplerenone (E); 3) losartan (L); and 4) cotreatment with eplerenone and losartan (EL). Ventricular epicardial activation mapping was performed on Langendorff-perfused hearts. Arrhythmia inducibility was tested by one to three premature stimuli and burst pacing. Longitudinal and transverse conduction velocity and dispersion of conduction were determined during pacing at a basic cycle length of 150 ms. Sirius red staining (collagen) was performed. As a result, in the RV of mice in the E, L, and EL groups, transverse conduction velocity was significantly increased and anisotropic ratio was significantly decreased compared with those values of mice in the C group. Anisotropic reentrant arrhythmias were induced in 52% of untreated mice and significantly reduced to 22%, 26%, and 16% in the E, L, and EL groups, respectively. Interstitial fibrosis was significantly decreased in both the RV and LV of all treated groups. Scattered patches of replacement fibrosis were found in 90% of untreated hearts, which were significantly reduced in the E, L, and EL groups. A strong correlation between the abundance of patchy fibrosis and arrhythmia inducibility was found. In conclusion, chronic RAAS inhibition limited aging-related interstitial fibrosis. The lower arrhythmogeneity of treated mice was directly correlated to the reduced amount of patchy fibrosis.
No takes yet. Share an insight, caveat, or question.
Stein et al. (2010) studied Aging-related myocardial fibrosis and arrhythmia vulnerability. Eplerenone, losartan, or cotreatment (eplerenone and losartan) vs. Untreated control was evaluated on Arrhythmia inducibility (anisotropic reentrant arrhythmias). Chronic RAAS inhibition with eplerenone, losartan, or both significantly reduced anisotropic reentrant arrhythmia inducibility from 52% in untreated mice to 22%, 26%, and 16%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: